MS Speaks

Multiple Sclerosis => TREATMENTS => TECFIDERA (dimethyl fumarate, BG-12, Fumaderm) => Topic started by: agate on August 20, 2020, 10:33:11 am

Title: (Abst.) PML in Tecfidera-treated MS patients
Post by: agate on August 20, 2020, 10:33:11 am
From PubMed (August 20, 2020)--"Progressive multifocal leucoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients":


https://pubmed.ncbi.nlm.nih.gov/32808554/


The researchers are affiliated with the Consortium of Multiple Sclerosis Centers (CMSC) and the University of Michigan.
Title: PML outcomes in MS patients treated with dimethyl fumarate
Post by: agate on November 13, 2022, 09:41:08 pm

Some Biogen researchers have published a report on MS patients being treated with dimethyl fumarate who developed PML.


From Multiple Sclerosis Journal (November 10, 2022)--"Progressive multifocal leucoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate":


https://journals.sagepub.com/doi/full/10.1177/20552173221132469
Title: Authors' correction to the previously cited article
Post by: agate on March 07, 2023, 09:35:49 pm
The authors of the article in the previous post in this thread have published a correction (Multiple Sclerosis Journal, February 27, 2023):


https://journals.sagepub.com/doi/full/10.1177/20552173231160312